Annovis Bio secures buntanetap patent
Analysis based on 8 articles · First reported Apr 02, 2026 · Last updated Apr 02, 2026
The issuance of this patent is expected to positively impact Annovis Bio's stock price and market valuation, as it strengthens the company's intellectual property and expands the potential applications of its lead drug candidate, buntanetap. This development could attract further investor interest in the biotechnology sector, particularly in companies focused on neurodegenerative disease treatments.
Annovis Bio, a Phase 3 clinical-stage biotechnology company, announced the issuance of U.S. Patent No. 12,582,632 B2. This patent covers the prevention and treatment of neurological injuries caused by brain infections through the administration of buntanetap, its investigational oral therapy. Buntanetap is being developed for neurodegenerative diseases like Alzheimer's disease and Parkinson's disease. The patent's significance lies in its potential to address neurodegeneration resulting from the overexpression of proteins during microbial and viral infections, a mechanism buntanetap targets by reducing neurotoxic aggregating proteins. Maria Maccecchini, President and CEO of Annovis Bio, highlighted the patent's importance in expanding the company's intellectual property estate and its commitment to patient benefit.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard